- Home
- IRD vs CEV Comparison
IRD vs CEV Comparison
Compare IRD & CEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- CEV
- Stock Information
- Founded
- IRD 2018
- CEV 1999
- Country
- IRD United States
- CEV United States
- Employees
- IRD N/A
- CEV N/A
- Industry
- IRD
- CEV Finance/Investors Services
- Sector
- IRD
- CEV Finance
- Exchange
- IRD NYSE
- CEV Nasdaq
- Market Cap
- IRD 60.9M
- CEV 67.8M
- IPO Year
- IRD N/A
- CEV N/A
- Fundamental
- Price
- IRD $1.12
- CEV $9.56
- Analyst Decision
- IRD Strong Buy
- CEV
- Analyst Count
- IRD 2
- CEV 0
- Target Price
- IRD $7.00
- CEV N/A
- AVG Volume (30 Days)
- IRD 151.1K
- CEV 19.6K
- Earning Date
- IRD 05-15-2025
- CEV 01-01-0001
- Dividend Yield
- IRD N/A
- CEV 4.23%
- EPS Growth
- IRD N/A
- CEV N/A
- EPS
- IRD N/A
- CEV 0.36
- Revenue
- IRD $13,651,000.00
- CEV N/A
- Revenue This Year
- IRD $22.00
- CEV N/A
- Revenue Next Year
- IRD $100.89
- CEV N/A
- P/E Ratio
- IRD N/A
- CEV $29.36
- Revenue Growth
- IRD N/A
- CEV N/A
- 52 Week Low
- IRD $0.65
- CEV $8.83
- 52 Week High
- IRD $2.18
- CEV $10.91
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- CEV 40.79
- Support Level
- IRD N/A
- CEV $9.56
- Resistance Level
- IRD N/A
- CEV $9.65
- Average True Range (ATR)
- IRD 0.00
- CEV 0.08
- MACD
- IRD 0.00
- CEV -0.01
- Stochastic Oscillator
- IRD 0.00
- CEV 26.50
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.